FFO
RLAY icon

Fortitude Family Office’s Relay Therapeutics RLAY Stock Holding History

Fortitude Family Office’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7K Buy
1,268
+863
+213% +$12.5K ﹤0.01% 476
2026
Q1 		$4.03K Buy
405
+104
+35% +$930 ﹤0.01% 1007
2025
Q4 		$2.55K Hold
301
– – ﹤0.01% 1077
2025
Q3 		$1.57K Buy
301
+145
+93% +$553 ﹤0.01% 1358
2025
Q2 		$540 Buy
+156
New +$464 ﹤0.01% 1766

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Fortitude Family Office's RLAY Position: Q2 2026 in Review

Fortitude Family Office increased its Relay Therapeutics (RLAY) stake by 213% in Q2 2026, buying an estimated $12.5K and bringing the position to 1,268 shares worth $23.7K. The position accounts for ﹤0.01% of the portfolio, ranked #476.

Fortitude Family Office first reported a position in RLAY in Q2 2025 and has held it in 5 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Fortitude Family Office held 1,268 shares of Relay Therapeutics worth $23.7K as of Q2 2026.
  • Fortitude Family Office bought 863 Relay Therapeutics shares in Q2 2026, an estimated $12.5K.
  • Relay Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #476 holding.
  • Fortitude Family Office first reported a position in Relay Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.